Egyptian International Pharmaceutical Investments (CAI:PHAR) LT-Debt-to-Total-Asset: 0.22 (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Egyptian International Pharmaceutical Investments CAI:PHAR

70 GF Score

Price E£88.31

GF Value E£59.83

Valuation Significantly Overvalued

12 Warning Signs

View Full Analysis

What is Egyptian International Pharmaceutical Investments LT-Debt-to-Total-Asset?

Egyptian International Pharmaceutical Investments CAI:PHAR +2.13% 70 LT-Debt-to-Total-Asset is 0.22 as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 70/100 and a GF Value™ of E£59.83 (Significantly Overvalued). The stock has 12 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Egyptian International Pharmaceutical Investments's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.22.

Egyptian International Pharmaceutical Investments's long-term debt to total assets ratio declined from Dec. 2024 (0.31) to Mar. 2026 (0.22). It may suggest that Egyptian International Pharmaceutical Investments is progressively becoming less dependent on debt to grow their business.

Egyptian International Pharmaceutical Investments (CAI:PHAR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Egyptian International Pharmaceutical Investments LT-Debt-to-Total-Asset Related Terms

Egyptian International Pharmaceutical Investments LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments LT-Debt-to-Total-Asset Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.10

0.12

0.28

0.31

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.31	0.28	0.29	0.28	0.22

70GF Score

Egyptian International Pharmaceutical Investments CAI:PHAR

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Egyptian International Pharmaceutical Investments LT-Debt-to-Total-Asset Calculation

Egyptian International Pharmaceutical Investments's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	4792.835	/	15372.957
	=	0.31

Egyptian International Pharmaceutical Investments's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	4033.703	/	18431.886
	=	0.22

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.22 mean?

Egyptian International Pharmaceutical Investments (CAI:PHAR) has a LT-Debt-to-Total-Asset of 0.22 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Egyptian International Pharmaceutical Investments and its competitors.

Is Egyptian International Pharmaceutical Investments' LT-Debt-to-Total-Asset too high?

Egyptian International Pharmaceutical Investments' current LT-Debt-to-Total-Asset is 0.22. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Egyptian International Pharmaceutical Investments' LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Egyptian International Pharmaceutical Investments' LT-Debt-to-Total-Asset of 0.22 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current LT-Debt-to-Total-Asset is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Egyptian International Pharmaceutical Investments stock overvalued right now?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.83, compared to a current price of E£88.31 — trading 47.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.22. Egyptian International Pharmaceutical Investments' overall GF Score™ is 70/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current LT-Debt-to-Total-Asset is 0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£88.31 is trading 47.6% above its estimated GF Value™ of E£59.83. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

LT-Debt-to-Total-Asset: 0.22
GF Value™: E£59.83 vs. price of E£88.31 (47.6% above fair value)
GF Score™: 70/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies CAI:RMDA CAI:NIPH CAI:MIPH XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM SHSE:688506

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY

Website http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.

70GF Score

Get the complete analysis for CAI:PHAR

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£88.31

Price

E£59.83

GF Value

View CAI:PHAR Analysis

See LT-Debt-to-Total-Asset data for all stocks →